Joint Preservation Therapy Solutions in Colorado Springs, CO

CDC PLACES vs. JH: two files, not one brochure

Joe Bradley will tell you the same thing he tells his own staff: epidemiology first, then MAC, then SKU. CDC PLACES (2023, crude) estimates 9% of adults in Colorado Springs have diagnosed diabetes — 3.0 points below the U.S. 12% figure. 9.9% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. Then we pick joint preservation therapy against that mix.

Epidemiology is not a protocol

• Adult arthritis here is 23.7% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 9.9% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Colorado.
• City-proper population of 483,956 is a Census figure, not a clinic count. It tells you the size of the catchment, not how many biologic vendors already call on the orthopedic group down the street.
• Colorado is outside CDC's historical Diabetes Belt core, but the national 12% diabetes figure still applies as a planning baseline until a clinic uses its own payer mix. Clinics asking for regenerative inventory still have to separate HCT/P 361 homologous-use products from unapproved “stem cell” claims (FDA 21 CFR 1271).

Uninsured mix and Medicare CTPs in the same building

JH reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Colorado Springs is 9% or not. PLACES is planning data. The LCD is the claim.

Before the first joint preservation therapy shipment